Business context and reporting period
This is MedTech Acquisition Corporation’s Form 10-K for the fiscal year ended December 31, 2022, filed March 22, 2023. Despite the company name in the request metadata, the filer was a pre-business-combination SPAC, not the operating TriSalus Life Sciences business. It reported no operating activity or revenue and was pursuing a merger with TriSalus; the proposed transaction had not closed as of the filing.
In December 2022, stockholders extended the SPAC’s deadline to complete a business combination to June 22, 2023. Holders redeemed 23,046,578 public shares for approximately $232.4 million, leaving 1,953,422 public shares outstanding.
Financial performance and position
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $0 | $0 |
| General and administrative expenses | $2.75 million | $3.04 million |
| Net income | $5.54 million | $4.77 million |
| Cash used in operating activities | $2.74 million | $1.74 million |
| Trust account interest income | $3.02 million | $64,000 |
Net income was not generated from operations: it included a $5.84 million noncash gain from the change in fair value of warrant liabilities and $3.02 million of trust-account interest, offset by expenses and $571,000 of income-tax provision. The 2021 comparison likewise included a $7.74 million warrant-liability gain. Operating margins are not meaningful because the SPAC had no revenue.
At year-end, cash outside the trust was $154,000, trust assets were $19.83 million, and total assets were $20.19 million. Working capital deficit was approximately $2.11 million, excluding income taxes payable. Total liabilities were $13.65 million, including $1.34 million under a sponsor convertible note, $944,000 in other related-party promissory notes, $1.06 million in warrant liabilities, and an $8.75 million deferred underwriting fee payable. Raymond James agreed to waive that deferred fee if the TriSalus transaction closes. The SPAC had no long-term debt or lease obligations disclosed.
The reported trust balance equated to approximately $10.14 per remaining public share at year-end. Trust funds were held in a demand deposit account after the company liquidated its prior investments in December 2022; management expected this to reduce future interest income.
Material changes and transaction outlook
- The company mutually terminated its proposed Memic transaction in March 2022 and signed the TriSalus merger agreement in November 2022.
- The proposed TriSalus consideration was $220 million in common shares valued at $10 per share. Closing required, among other conditions, at least $60 million of available closing cash, stockholder approvals, Nasdaq listing approval, and at least $5,000,001 of net tangible assets.
- A 2022 federal law extended transitional pass-through payment status for TriSalus’s TriNav Infusion System through December 31, 2023, satisfying the agreement’s reimbursement-related payment condition.
- The filing described a non-binding Magnetar term sheet for $25 million to $50 million of 8% senior secured convertible notes at closing, with a potential later option for additional notes. Funding remained subject to due diligence, definitive documents, and other conditions; the filing stated $25 million was then potentially subject to funding. Separately, the merger agreement allowed termination if at least $40 million of private financing commitments were not obtained by March 31, 2023.
- The sponsor had agreed to forfeit 2,187,500 shares and subject another 3,125,000 shares to vesting restrictions if the transaction closed; those undertakings would be void if the relevant agreements were terminated.
Risks, contingencies, and unusual items
Management and the auditor identified substantial doubt about the company’s ability to continue as a going concern because of limited operating cash and the June 22, 2023 business-combination deadline. If no transaction closes by then, the company must liquidate; warrants would expire worthless. The financial statements contain no liquidation adjustments.
Other material risks include substantial redemption activity, dependence on additional financing, possible creditor claims against trust assets, uncertainty that sponsor indemnification could be funded, potential dilution from securities issued to finance the transaction, and conflicts of interest involving the sponsor and management. The filing also noted potential exposure to a 1% federal excise tax on certain post-2022 redemptions, and broader uncertainty from inflation, interest rates, COVID-19, and geopolitical events.
The fair value change in warrant liabilities materially affected reported earnings and depended in part on valuation estimates. Management reported effective disclosure controls and internal control over financial reporting as of year-end; the auditor did not provide an internal-control attestation.
Most important facts for investors to verify
- Whether the TriSalus merger closed, and the final terms, approvals, redemptions, and resulting ownership and dilution.
- Whether required financing and the $60 million available-cash closing condition were met; confirm the definitive status and terms of any Magnetar financing.
- The company’s actual cash, trust balance, and redemption value per share at the transaction or liquidation date, including any taxes, fees, or creditor claims.
- Whether the June 22, 2023 deadline was extended again or the SPAC liquidated, and the resulting treatment of public shares and warrants.
- TriSalus’s operating results, cash needs, reimbursement outlook, and risks in its separate filings and transaction disclosures; this SPAC 10-K does not provide a clear operating-company financial picture for TriSalus.